Convergent Therapeutics Inc., a clinical stage radiopharmaceutical company, and IONETIX Corporation, a cyclotron technology and isotope manufacturing company, recently announced a long-term supply agreement for the therapeutic medical radioisotope, actinium-225 (Ac-225). The agreement will support Convergent’s pipeline of next-generation radiotherapies including its lead asset, CONV01-α, a prostate-specific membrane antigen, a (PSMA)-targeted monoclonal antibody linked to Ac-225. CONV01-α is currently being investigated as a potentially groundbreaking treatment for prostate cancer.
To
read more please visit:
Source: IONETIX